Operable node-positive breast cancer:

• Most suspicious lymph node clipped
• AJCC/UICC stage II-III
• Eligible for primary axillary lymph node dissection or sentinel lymph node biopsy procedure

TAXIS**
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy. All patients will receive breast/chest wall and regional nodal irradiation. Patients without axillary lymph node dissection will receive additional irradiation of the axilla.

Operable HER2-positive or triple-negative breast cancer:

• cT1c-T3 prior to neoadjuvant systemic therapy (NAST) and
• cN0/iN0
• Standard NAST with radiological complete response

EUBREAST-01
Omission of sentinel lymph node biopsy in patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy. All patients with confirmed breast pCR after lumpectomy will be selected for the single study arm leading to omission of any axillary treatment.

Operable triple-negative breast cancer:

• Stage II-III
• Pathological tumor size >2 cm if pN0

ALEXANDRA
Arm A: Adjuvant chemotherapy with 12x paclitaxel weekly followed by EC/AC q2w + atezolizumab q2w followed by atezolizumab monotherapy q3w (total duration of atezolizumab will be one year)
Arm B: Chemotherapy alone

Operable HR-positive / HER2-negative breast cancer:

• Age ≥ 70 years; Stage II-III
• Adjuvant chemotherapy required and feasible

APPALACHES
Arm A: Palbociclib 2 years + standard adjuvant endocrine therapy ≥ 5 years
Arm B: Adjuvant chemotherapy followed by standard adjuvant endocrine therapy ≥ 5 years

HER2-negative breast cancer, non-pCR after NACT

• HR-negative (TNBC)

or

• HR-positive with CPS-EG score ≥3 or 2 and ypN+
•  At least 16 weeks of taxane-based chemotherapy

SASCIA
Arm A: Sacituzumab govitecan 8 cycles d1,8 q3w
Arm B: Treatment of physician`s choice (8 cycles capecitabine or platinum-based chemotherapy or observation)
In patients with HR-positive breast cancer, endocrine therapy will be administered according to local guidelines.

HER2-positive breast cancer, non-pCR after NACT

• cT4, cN0-3 or cT1-3, cN2-3 at first diagnosis

or

• cT1-3, cN0-1 at first diagnosis with ypN1-3 after NACT
• An interval of ≤12 weeks between the date of last surgery and the date of randomization
• At least 16 weeks chemotherapy, including at least 9 weeks of trastuzumab (± pertuzumab) and at least 9 weeks of taxane-based chemotherapy

TruDy/DESTINY-B05
Arm A: Trastuzumab deruxtecan 14 cycles d1 q3w
Arm B: Trastuzumab emtansine (T-DM1) 14 cycles d1 q3w

HER2-positive, HR-positive breast cancer

• cT1c-T3 prior to neoadjuvant treatment
• Centrally confirmed PIK3CA mutation (tumor)
• BMI ≤ 30

GeparPiPPa**
Arm A: Endocrine therapy in combination with ready-to-use fixed-dose combination of pertuzumab and trastuzumab s.c. (PH-FDC SC) q3w and inavolisib (6 cycles)
Arm B: Endocrine therapy and PH-FDC SC q3w (6 cycles)

Brain metastases of breast cancer

Brain Metastases in Breast Cancer (BMBC)
Retrospective and prospective registry designed to collect tumor characteristics of the primary and metastatic tumor as well as treatment data and biomaterial from patients diagnosed with brain metastases of breast cancer.

HER2-negative and HR-positive metastatic breast cancer :

• 1st systemic therapy for the treatment of metastatic breast cancer
• Patients with only asymptomatic oligometastases of the bone as the only site of metastatic disease are excluded

PADMA
Endocrine therapy + palbociclib versus mono-chemotherapy +/- endocrine maintenance therapy
Possible mono-chemotherapies (Physician`s choice):

• Capecitabine p.o.
• Epirubicin i.v.
• Paclitaxel i.v.
• Vinorelbine i.v.

• Patients with breast cancer during pregnancy
  Non-pregnant women with breast cancer < 40 years
  M1 possible
  

• Women with a confirmed or likely deleterious BRCA1 germline mutation
• Age ≥ 25 years and ≤ 55 years
• No evidence of breast cancer
  No preventive breast surgery planned
• No previous history of breast or ovarian cancer
  

BRCA-P**
Study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation:
Denosumab 120mg s.c. every 6 months vs placebo s.c. every 6 months

Former GBG study participants in Germany

Patient self-reported outcome registry (PSRO)
Collection of long-term safety and efficacy parameters of former GBG study participants from prospective clinical trials. Data reporting by the patient via questionnaire.

Former GBG study participants other countries

ETERNITY-B
Registry for collection of long-term safety and efficacy parameters of former GBG study participants from prospective clinical trials. Data collection and documentation is performed study site.